CellSeed Inc. (7776.T)
- Previous Close
546.00 - Open
544.00 - Bid 546.00 x --
- Ask 547.00 x --
- Day's Range
536.00 - 564.00 - 52 Week Range
211.00 - 1,160.00 - Volume
1,257,200 - Avg. Volume
2,065,587 - Market Cap (intraday)
18.928B - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
-- - EPS (TTM)
-25.72 - Earnings Date Aug 12, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
www.cellseed.comRecent News: 7776.T
View MorePerformance Overview: 7776.T
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 7776.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 7776.T
View MoreValuation Measures
Market Cap
18.93B
Enterprise Value
16.94B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
97.93
Price/Book (mrq)
8.75
Enterprise Value/Revenue
87.63
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.81%
Return on Equity (ttm)
-71.66%
Revenue (ttm)
161M
Net Income Avi to Common (ttm)
-914M
Diluted EPS (ttm)
-25.72
Balance Sheet and Cash Flow
Total Cash (mrq)
930M
Total Debt/Equity (mrq)
15.50%
Levered Free Cash Flow (ttm)
-580.63M